HIV and Hepatitis.com Coverage of the
13th Annual Conference on Retroviruses and Opportunistic Infections
February 5 - 8, 2006, Denver, CO

Boosted Protease Inhibitors

Combination of Boosted Tipranavir and Experimental PI TMC 125 Is Not Recommended - 2/28/06

Boehringer Ingelheim Announces 48-week Results from Tipranavir RESIST Studies

New 48 Week Clinical Trial Data Report on Atazanavir with or without Ritonavir in Treatment-naive Patients